The Zhitong Finance App learned that on Wednesday, Monte Rosa Therapeutics (GLUE.US) surged more than 42% in the premarket to $22.76. According to the news, mid-term data from Monte Rosa Therapeutics' ongoing MRT-8102 phase 1 trial showed a decrease in C-reactive protein levels in cardiovascular and cardiometabolic diseases.

Zhitongcaijing · 4d ago
The Zhitong Finance App learned that on Wednesday, Monte Rosa Therapeutics (GLUE.US) surged more than 42% in the premarket to $22.76. According to the news, mid-term data from Monte Rosa Therapeutics' ongoing MRT-8102 phase 1 trial showed a decrease in C-reactive protein levels in cardiovascular and cardiometabolic diseases.